tirzepatide for maintenance therapy on semaglutide or Tirzepatide Tier 1 Maintenance Dosing

It is not addictive , not a stimulant , and not hormone-based

The absence of a dose- relationship was attributed to the increased mortality rate at 182 mg/m 3

Ozempic may be prescribed on the NHS when: The patient has a confirmed diagnosis of type 2 diabetes mellitus It is used as part of a treatment strategy that includes triple therapy or where insulin is not appropriate The patient has a BMI 35 kg/m (or 30 kg/m in people of certain ethnicities with increased diabetes risk) or weight-related comorbidities The patient has specific problems with high-dose insulin or would benefit from weight loss Continuation criteria apply at 6 months: treatment should only continue if there has been a beneficial metabolic response (reduction in HbA1c of at least 11 mmol/mol [1%] and weight loss of at least 3% of initial body weight)

The improvement in serum testosterone levels observed after just two months of therapy is particularly noteworthy